Perspective Therapeutics to Participate in Upcoming February Investor Conferences
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, ...
Spectral Medical Provides January Tigris Trial Update
Strong enrollment activity to start 2025146 patients enrolledTORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or ...
Targeted Oncology24d
FDA Clears 225Ac-SSO110 for Phase 1/2 SCLC and Merkel Cell Carcinoma Trial
The agent is being developed together with 68 Ga-SSO120 as part of a theranostic approach for targeted radionuclide therapy. In addition, Ariceum, the developer of 225 Ac-SSO110, has recently ...
C&EN28d
Advances in Preclinical Research of Theranostic Radiopharmaceuticals in Nuclear Medicine
State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education ...